Company Overview of Angiochem Inc.
Angiochem Inc., a clinical-stage biotechnology company, engages in discovering and developing peptide drug conjugates for the treatment of neurological diseases. The company focuses on developing small molecules and biologics for the treatment of a range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases, pain, and other diseases. It develops ANG1005, a taxane derivative that leverages low density lipoprotein receptor-related protein 1 (LRP-1) to cross the blood-brain barrier (BBB) and enter cancer cells; peptide antibody conjugates; ANG4043, an anticancer therapy to treat breast cancer metastases in the brain; antibody-drug conjugates that cross th...
201 President-Kennedy Avenue
Montreal, QC H2X 3Y7
Founded in 2003
Key Executives for Angiochem Inc.
Vice President of Development
Director of Corporate Development
Compensation as of Fiscal Year 2015.
Angiochem Inc. Key Developments
Angiochem Inc. Presents at Boston CEO Conference, Jun-04-2014 01:45 PM
Jun 2 14
Angiochem Inc. Presents at Boston CEO Conference, Jun-04-2014 01:45 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Jean-Paul Castaigne, Chairman, Chief Executive Officer and President.
Angiochem Demonstrates Peptide Antibody Conjugate That Successfully Crosses the Blood Brain Barrier and Increases Survival in HER-2 Positive Brain Tumors
Dec 16 13
Angiochem announced that its peptide-antibody conjugate, ANG4043 successfully crosses the BBB, reduces tumor size and significantly increases survival in mice with intracranial HER2-positive brain tumors. These results underscore the potential for development of novel antitumor therapeutics for neuro-oncology indications. The data presentation revealed that the company's technology has been successfully applied to monoclonal antibodies (mAbs) for creation of brain-penetrant antibody conjugates of anti-Human Epidermal Growth Factor Receptor 2 (HER2). Angiochem researchers described the ANG4043 preclinical results, including: In vivo, in mice that were implanted intracranially with HER2+ human breast tumor cells (BT-474), it was observed: ANG4043 crosses the BBB and reaches the tumor using near-infrared imaging, where a strong signal is observed in brain following IV administration of fluorescent ANG4043, but not of fluorescent anti-HER2. Reduction in tumor size correlating with increased survival. In vitro, ANG4043 binding affinity for HER2 receptor and anti-proliferative properties were similar to the native, unconjugated mAb.
Angiochem Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 01:30 PM
Nov 15 13
Angiochem Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 01:30 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|